Home » Stocks » Inhibikase Therapeutics

Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: $10.00 - $12.00
Current IPO price range

Stock Price Chart

Key Info

Market Cap 115.66M
Revenue (ttm) 802,425
Net Income (ttm) -4.53M
Shares Out 10.51M
EPS (ttm) -0.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

More Stats

Market Cap 115.66M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 10.51M
Float n/a
EPS (basic) n/a
EPS (diluted) -0.43
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield -3.92%
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 144.14
PB Ratio n/a
Revenue 802,425
Operating Income n/a
Net Income -4.53M
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share n/a
Gross Margin n/a
Operating Margin n/a
Profit Margin -565.01%
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in USD.

Financial Overview

Revenue Growth-72.22%-
Net Income / Loss-5,722,983-2,152,453
Numbers in USD.

Company Profile

Company Details

Full Name Inhibikase Therapeutics, Inc.
Country United States
Employees 2
CEO Milton H. Werner

Stock Information

Ticker Symbol IKT
Stock Exchange NASDAQ
Unique Identifier NASDAQ: IKT
IPO Date Pending


Inhibikase Therapeutics is a clinical stage pharmaceutical company developing therapeutics for Parkinson’s Disease, or PD, and related disorders that arise inside and outside of the brain. We filed two Investigational New Drug, or IND, applications with the U.S. Food and Drug Administration, or FDA, in the first quarter of 2019 for our lead asset candidate, IkT-148009. One IND is for the treatment of Parkinson’s Disease, while the second is for treatment of gastrointestinal, or GI, complications that arise as early symptoms of PD in patients. We initiated clinical development of IkT-148009 for the treatment of PD in 2019. First dosing of patients for treatment of PD is expected to commence shortly after the conclusion of this offering. Clinical development of IkT-148009 for the GI complications in PD patients will cross-reference the first human study of IkT-148009 for the treatment of PD.